Application of phosphorylated protein in membranous nephropathy

Abstract

The invention discloses application of a reagent for quantitatively detecting the phosphorylation level of a T567 site of a protein EZR in preparation of a membranous nephropathy diagnostic reagent. In the research process, the applicant finds that the phosphorylation level of the EZR phosphorylation site T567 is obviously reduced in an IMN group compared with a control group, and the phosphorylation level is possibly gradually reduced along with disease progression. Downregulation of the phosphorylation level of T567 may participate in podocyte damage in the IMN disease progression process. And the statistical results of the immunohistochemical staining intensity and the cell positive rate of the slice further prove that the phosphorylation level of the EZRT567 site is indeed reduced in the renal biopsy tissue of the IMN patient, so that the membranous nephropathy can be diagnosed through the reagent capable of quantitatively detecting the phosphorylation level of the T567 site of the protein EZR.

Description

technical field [0001] The application relates to the technical field of nephropathy, in particular to the application of phosphorylated protein in membranous nephropathy. Background technique [0002] Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults. According to different etiologies, MN can be divided into idiopathic membranous nephropathy (IMN) and secondary membranous nephropathy (SMN), of which IMN accounts for about 75%, and the etiology is unknown; SMN etiology is relatively clear , tumors, infections, drugs, autoimmune diseases such as systemic lupus erythematosus, etc. can lead to SMN. Patients with MN usually present with severe proteinuria, edema, hypoalbuminemia, and hyperlipidemia, and the diagnosis depends on the pathology of renal biopsy. With capillary wall deposition, electron microscopy shows the formation of electron-dense material under the visceral epithelial cells of the glomeruli; however, IMN can only be diagnosed...

AI Technical Summary

Problems solved by technology

Although some research results have been achieved in IMN disease markers and pathogenesis, the key trigger source of the disease, complement activation mechanism and the specific molecular mechanism leading to podocyte damage have not been fully clarified, which also poses a challenge to the diagnosis and clinical diagnosis of IMN. Treatment brings certain difficulties. Once patients enter the stage of ESRD, they will face more serious physical, psychological and social burdens.

Images